On Demand 2017 Complications of PID (MOC)

Price: $25 members, $35 non-members

You can earn up to 1.75 AMA PRA Category 1 Credits™, and up to 1.75 MOC Part II Self-Assessment credits. 

Many primary immunodeficiency disorders (PID) present with signs and symptoms of immune dysregulation. National data on non-infectious complications of PID is presented, along with a discussion of the evaluation of patients. Current information on the use of biologicals to treat specific immune deficiencies, as well as advances in this area, are highlighted.

  • What We Know: Data From USIDNet on the Frequency of Non-infectious Complications of PID
  • What We Need to Know: Evaluation of PID Patients With Immune Dysregulation
  • Where Are We Going? Personalized Therapy for Monogeneic Immune Deficiency With Immune Dysregulation

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Of the AMA PRA Category 1 Credits™ listed above, the ABAI has designated a maximum of 1.75 credits as meeting the requirements for MOC Part II Self-Assessment.

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Describe the frequency of non-infectious complications of primary immunodeficiency.
  • Recognize the manifestations of non-infectious complications of primary immunodeficiency and the appropriate evaluation of the patient.
  • Be aware of the therapeutic options available for the treatment of monogeneic immunodeficiencies, including monoclonal antibodies.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (College) policy, the College must identify and resolve conflicts of interest for all individuals responsible for the development, management, presentation, or evaluation of content for a CME activity. Financial disclosures are reviewed in advance, to ensure any potential conflicts of interest are resolved. Disclosure in no way implies that the information presented is biased or of lesser quality; it is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Specific disclosure information for the 2017 Annual Meeting is conveniently located online at college.acaai.org/disclosures

Course summary
Available credit: 
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 Attendance
Course opens: 
10/30/2017
Course expires: 
10/30/2020
Cost:
$35.00
Rating: 
0
  • Richard L. Wasserman, MD, PhD, FACAAI
  • Kathleen Sullivan, MD, PhD
  • Troy Torgersen, MD, PhD
  • Jennifer Leiding, MD

Available Credit

  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 Attendance

Accreditation Period

Course opens: 
10/30/2017
Course expires: 
10/30/2020

Price

Cost:
$35.00
Please login or create an account to take this course.